Shu Chunlu, Zhu Daxing, Zhou Qinghua
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu 610041, China.
Lung Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Zhongguo Fei Ai Za Zhi. 2022 Feb 20;25(2):130-136. doi: 10.3779/j.issn.1009-3419.2022.102.04.
Surgery is the standard treatment for resectable non-small cell lung cancer (NSCLC). Neoadjuvant and adjuvant therapy have been widely used for preventing recurrence and metastasis. Immune checkpoint inhibitors (ICIs) have brought long-term survival benefits in advanced NSCLC and showed higher downstage rates and pathological remission in the neoadjuvant setting. Predictive biomarkers are of great significance to identify the beneficiaries of neoadjuvant ICIs. At present, the biomarkers are still inconclusive. We summarized the clinical trials of neoadjuvant immune checkpoint inhibitors that have been disclosed so far, and reviewed the progress of the biomarkers associated with those trials. .
手术是可切除非小细胞肺癌（NSCLC）的标准治疗方法。新辅助治疗和辅助治疗已被广泛用于预防复发和转移。免疫检查点抑制剂（ICIs）已为晚期NSCLC带来长期生存益处，并在新辅助治疗中显示出更高的降期率和病理缓解率。预测性生物标志物对于识别新辅助ICIs的受益患者具有重要意义。目前，生物标志物仍不明确。我们总结了迄今为止已披露的新辅助免疫检查点抑制剂的临床试验，并回顾了与这些试验相关的生物标志物的进展。
